OlympiAD Trial is a phase III study which enrolled MBC patients with both triple-negative and HR+/HER2- tumours carrying a BRCA1/2 germline mutation, who had received a maximum of two lines of chemotherapy, to receive the PARPi olaparib or physician’s choice single-agent chemotherapy. Here, BRCA1 is linked to neoplasm.